(Q48906281)

16 February 2018

title

A 12-year follow-up in sporadic inclusion body myositis: an end stage with major disabilities. (English)

1 reference

16 February 2018

main subject

inclusion body myositis

1 reference

2

1 reference

16 February 2018

Jacob K. Sont

3

1 reference

16 February 2018

author name string

Fieke M Cox

1

1 reference

16 February 2018

Axel R Wintzen

4

1 reference

16 February 2018

Jan J G M Verschuuren

5

1 reference

16 February 2018

Umesh A Badrising

6

1 reference

16 February 2018

language of work or name

English

0 references

publication date

9 September 2011

1 reference

16 February 2018

published in

Brain

1 reference

16 February 2018

volume

134

1 reference

16 February 2018

issue

Pt 11

1 reference

16 February 2018

page(s)

3167-3175

1 reference

16 February 2018

Comparison of weakness progression in inclusion body myositis during treatment with methotrexate or placebo.

cites work

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWR217

Epidemiology of inclusion body myositis in the Netherlands: a nationwide study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWR217

Inclusion body myositis. Clinical features and clinical course of the disease in 64 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWR217

The Rivermead Mobility Index: a further development of the Rivermead Motor Assessment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWR217

Detecting dysphagia in inclusion body myositis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWR217

Sporadic inclusion body myositis--diagnosis, pathogenesis and therapeutic strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWR217

Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWR217

Inclusion body myositis: current pathogenetic concepts and diagnostic and therapeutic approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWR217

Dysphagia in inclusion body myositis: clinical features, management, and clinical outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWR217

Mechanical ventilation for amyotrophic lateral sclerosis/motor neuron disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWR217

What determines quality of life in inclusion body myositis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWR217

Inclusion body myositis: new concepts

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWR217

Diaphragmatic dysfunction in patients with idiopathic inflammatory myopathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWR217

Hand-held myometry: reference values

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWR217

Euthanasia and physician-assisted suicide among patients with amyotrophic lateral sclerosis in the Netherlands.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWR217

Primary respiratory failure in inclusion body myositis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWR217

21 January 2018

Identifiers

DOI

10.1093/BRAIN/AWR217

1 reference

16 February 2018

1 reference

16 February 2018